Radiotherapy in combination with vascular-targeted therapies
Open Access
- 1 January 2010
- journal article
- Published by Walter de Gruyter GmbH in Radiology and Oncology
- Vol. 44 (2), 67-78
- https://doi.org/10.2478/v10019-010-0025-9
Abstract
Background. Given the critical role of tumor vasculature in tumor development, considerable efforts have been spent on developing therapeutic strategies targeting the tumor vascular network. A variety of agents have been developed, with two general approaches being pursued. Antiangiogenic agents (AAs) aim to interfere with the process of angiogenesis, preventing new tumor blood vessel formation. Vascular-disrupting agents (VDAs) target existing tumor vessels causing tumor ischemia and necrosis. Despite their great therapeutic potential, it has become clear that their greatest clinical utility may lie in combination with conventional anticancer therapies. Radiotherapy is a widely used treatment modality for cancer with its distinct therapeutic challenges. Thus, combining the two approaches seems reasonable. Conclusions. Strong biological rationale exist for combining vascular-targeted therapies with radiation. AAs and VDAs were shown to alter the tumor microenvironment in such a way as to enhance responses to radiation. The results of preclinical and early clinical studies have confirmed the therapeutic potential of this new treatment strategy in the clinical setting. However, concerns about increased normal tissue toxicity, have been raised.Keywords
This publication has 103 references indexed in Scilit:
- Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411Journal of Clinical Oncology, 2009
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyJournal of Clinical Oncology, 2009
- Electrochemotherapy in treatment of tumoursEuropean Journal of Surgical Oncology, 2008
- Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcomaBritish Journal of Cancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Molecular regulation of vessel maturationNature Medicine, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971